Madison Carlino
Policy Analyst, Reason Foundation
Madison S. Carlino is a policy analyst at Reason Foundation. Her work primarily focuses on drug policy in the United States, including psychedelic medicine and marijuana laws.
Before joining Reason, Carlino worked as a research intern and grant writer with the James Madison Institute in Tallahassee, where she focused on education policies that empower Florida parents to choose schools, courses, resources, and programs that fit their child's unique needs, interests, and learning styles. Her research also emphasized the role of constitutional rights in promoting democracy and freedom.
As an undergraduate, Carlino was a policy analyst at Florida State University's DeVoe L. Moore Center. During her tenure there, she developed and conducted a research project examining the relationship between Cuban enclaves and Cuban wages in Miami.
Carlino graduated summa cum laude with a B.S. in economics from Florida State University, where she double-majored in economics and media/communication studies with a minor in business.
-
Ibogaine offers major promise in treating addiction, mental health
Ibogaine has the potential to transform the lives of millions of Americans struggling with addiction and mental health challenges.
-
California bill would establish a psilocybin pilot program for veterans, first responders
Senate Bill 751 proposes the creation of a pilot program to investigate the use of psilocybin services for veterans and inactive first responders.
-
Nevada Assembly Bill 378 could help patients access psychedelic therapies
An Alternative Therapy Pilot Program could expand access to innovative treatments for individuals suffering from mental health conditions in Nevada.
-
Washington has a chance to examine ibogaine-assisted therapy benefits
Washington Senate Bill 5204 would allow research into ibogaine-assisted therapy, a promising potential treatment for opioid use disorder.
-
DEA’s increased DMT quota signals positive advancement in psychedelic research
The Drug Enforcement Administration has raised the 2025 legal production quota for the psychedelic DMT from 11,000 grams to 20,000 grams.
-
Rethinking the need for double-blind placebo trials in psychedelic clinical investigations
Alternative trial designs recognize the distinct nature of psychedelics and ensure that promising therapies can meet regulatory standards.
-
Psychedelic treatment for neurodegenerative disorders
Recent research suggests that psychedelics, such as psilocybin and LSD, show strong potential as effective treatments for neurodegenerative disorders.
-
Psychedelic therapy offers possible new hope for Alzheimer’s disease sufferers
Nearly 6.9 million Americans aged 65 and older suffer from Alzheimer’s, facing a progressive decline that current treatments cannot stop or reverse.
-
Batch-tracking: The next wave of marijuana tracking systems
Maine recently implemented a first-of-its-kind system to track marijuana sales, setting a new standard for the industry.
-
No, Florida’s marijuana measure won’t create a cannabis monopoly—as long as lawmakers don’t screw it up
Preventing monopolization in Florida’s marijuana market requires focusing on creating accessible and fair conditions for all businesses.
-
Examining court rulings and state and federal laws on marijuana users’ gun rights
Government should not be able to restrict an individual’s Second Amendment right to possess a firearm due to their legal marijuana consumption.
-
Colorado could improve regulatory rules regarding psychedelic use
As Colorado establishes an operating regulatory framework for The Natural Medicine Health Act, there is room for improvement in rulemaking.
-
Alaska considers much needed reduction in marijuana taxes
A drastic tax cut is warranted to place legal products on a more even playing field with illicit alternatives.
-
Examining the 2024 state marijuana legalization proposals
Right now, 24 states have legalized the recreational use of marijuana by adults—a rapid shift after Colorado and Washington first did so in 2012.
-
Ibogaine treatment for opioid use disorder
Policymakers should consider ibogaine as a potential alternative treatment for opioid use disorder.
-
Florida’s attorney general challenges marijuana initiative with spurious arguments
Florida voters have the chance to vote on a marijuana ballot initiative, but Florida politicians are trying to keep that from happening.
-
Survey shows stereotype of the lazy, lefty marijuana smoker doesn’t reflect reality
Marijuana users come from all different backgrounds and are not restricted to a particular political affiliation, education level, income bracket, career position, or location.
-
The Breakthrough Therapies Act could spur research and improve access to life-saving drugs
The Breakthrough Therapies Act would pave the way for more accessible and innovative mental health treatments while also enabling state-level adaptation.
